Markus Hansson
- Hematology top 1%
- Multiple Myeloma Research and Treatments 43
- Immunology top 2%
- Immune Cell Function and Interaction 19
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 10
- Mast cells and histamine 9
- Oncology top 5%
- Peptidase Inhibition and Analysis 13
- Cancer Treatment and Pharmacology 9
- Immunology and Allergy top 10%
- Genetics top 10%
-
- Protein Degradation and Inhibitors 22
-
- Monoclonal and Polyclonal Antibodies Research 7
- Co-authors
- Kristoffer HellstrandSvante HermodssonMats BruneInge OlssonWilliam M. NauseefAlexzander AseaUlf‐Henrik MellqvistRaymond M. Welsh
- Cited by
- HematologyImmunologyOncology
- Partner nations
- SwedenUnited StatesDenmark
In The Last Decade
Markus Hansson
85 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 102
- Hematology 672
- Immunology 980
- Oncology 488
- Immunology and Allergy 75
- Genetics 117
Countries citing papers authored by Markus Hansson
This map shows the geographic impact of Markus Hansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Hansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Hansson more than expected).
Fields of papers citing papers by Markus Hansson
This network shows the impact of papers produced by Markus Hansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Hansson. The network helps show where Markus Hansson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Markus Hansson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 3 | |
| 6 | 2022 | 10 | |
| 7 | 2020 | 26 | |
| 8 | 2018 | 27 | |
| 9 | 2018 | 12 | |
| 10 | 2018 | 3 | |
| 11 | 2018 | 3 | |
| 12 | Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial | 2017 | 0 |
| 13 | 2016 | 17 | |
| 14 | 2015 | 42 | |
| 15 | ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010) | 2015 | 3 |
| 16 | 2014 | 9 | |
| 17 | 2013 | 62 | |
| 18 | 2006 | 13 | |
| 19 | 2005 | 166 | |
| 20 | 1996 | 58 |
About Markus Hansson
Markus Hansson is a scholar working on Hematology, Immunology, Oncology, Genetics and Molecular Biology, having authored 89 papers that have together received 2.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (43 papers), Protein Degradation and Inhibitors (22 papers), Immune Cell Function and Interaction (19 papers), Peptidase Inhibition and Analysis (13 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (10 papers), Cancer Treatment and Pharmacology (9 papers), Mast cells and histamine (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). The work is most often cited by research in Hematology (672 citations), Immunology (980 citations), Oncology (488 citations), Immunology and Allergy (75 citations) and Genetics (117 citations). Markus Hansson has collaborated with scholars based in Sweden, United States and Denmark. Frequent co-authors include Kristoffer Hellstrand, Svante Hermodsson, Mats Brune, Inge Olsson, William M. Nauseef, Alexzander Asea, Ulf‐Henrik Mellqvist, Raymond M. Welsh, Rolf Kiessling and Cláes Dahlgren. Their work appears in journals such as Blood, European Journal Of Haematology, Haematologica, Journal of Leukocyte Biology and Experimental Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.